Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold (Paid Option) |
|
as soon as is submitted to ZB.
Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
Clin. Microbiol. Infect. 30, 1131-1138 (2024)
BACKGROUND: Tuberculosis (TB) is the leading cause of mortality by an infectious disease world-wide. Despite national and international efforts, the world is not on track to end TB by 2030. Antibiotic treatment of TB is longer than for most infectious diseases and complicated by frequent adverse events. To counter emerging Mycobacterium tuberculosis drug resistance and provide effective, safe drug treatments of shorter duration, novel anti-TB medicines and treatment regimens are needed. Through a joint global effort, more candidate medicines are in the clinical phases of drug development than ever before. OBJECTIVES: To review anti-TB medicines and treatment regimens under clinical evaluation for the future treatment of drug-susceptible and drug-resistant TB. SOURCES: Pre-clinical and clinical studies on novel anti-TB drugs. CONTENT: Description of novel protein synthesis inhibitors (oxazolidinones and oxaboroles), respiratory chain inhibitors (diarylquinolines and cytochrome bc1 complex inhibitor), cell wall inhibitors (DprE1 inhibitors, thioamides and carbapenems) and cholesterol metabolism inhibitor currently evaluated in clinical trials and novel clinical trial platforms for the evaluation of treatment regimens, rather than single entities. IMPLICATIONS: A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Clinical Trials ; Drug Classes ; Platform Trials ; Tb ; Unite4tb; Mycobacterium-tuberculosis; Resistant Tuberculosis; Drug; Bedaquiline; Pretomanid; Delamanid; Moxifloxacin; Q203
ISSN (print) / ISBN
1198-743X
e-ISSN
1469-0691
Quellenangaben
Volume: 30,
Issue: 9,
Pages: 1131-1138
Publisher
Wiley
Publishing Place
125 London Wall, London, England
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Research Unit Global Health (UGH)
Grants
German Ministry for Edu-cation and Research (BMBF)
EDCTP2 programme
German Center for Infection Research (DZIF)
German Center of Infection Research
Bill & Melinda Medical Research Institute
Otsuka Novel Products GmbH
EDCTP2 programme
German Center for Infection Research (DZIF)
German Center of Infection Research
Bill & Melinda Medical Research Institute
Otsuka Novel Products GmbH